Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Jul;72(1):278–286. doi: 10.1172/JCI110967

Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion.

T F Tse, W E Clutter, S D Shah, P E Cryer
PMCID: PMC1129183  PMID: 6135707

Abstract

The transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion is not solely attributable to dissipation of insulin and, therefore, must also involve factors that actively raise the plasma glucose concentration--glucose counterregulatory factors. We have shown that the secretion of two of these, glucagon and epinephrine, is specific for glucose ingestion and temporally related to the glucose counterregulatory process. To determine the physiologic roles of glucagon and epinephrine in postprandial glucose counterregulation, we produced pharmacologic interventions that resulted in endogenous glucagon deficiency with and without exogenous glucagon replacement, adrenergic blockade, and adrenergic blockade coupled with glucagon deficiency starting 225 min after the ingestion of 75 g of glucose in normal subjects. Also, we assessed the effect of endogenous epinephrine deficiency alone and in combination with glucagon deficiency late after glucose ingestion in bilaterally adrenalectomized subjects. Glucagon deficiency resulted in nadir plasma glucose concentrations that were approximately 30% lower (P less than 0.01) than control values, but did not cause hypoglycemia late after glucose ingestion. This effect was prevented by glucagon replacement. Neither adrenergic blockade nor epinephrine deficiency alone impaired the glucose counterregulatory process. However, combined glucagon and epinephrine deficiencies resulted in a progressive fall in mean plasma glucose to a hypoglycemic level late after glucose ingestion; the final glucose concentration was 40% lower (P less than 0.02) than the control (epinephrine deficient) value in these patients, and was nearly 50% lower (P less than 0.001) than the control value and approximately 30% lower (P less than 0.05) than the glucagon-deficient value in normal subjects. We conclude (a) the transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion is the result of the coordinated diminution of insulin secretion and the resumption of glucagon secretion. (b) Epinephrine does not normally play a critical role in this process, but enhanced epinephrine secretion compensates largely and prevents hypoglycemia when glucagon secretion is deficient.

Full text

PDF
278

Images in this article

280FIGURE 1
on p.280
280FIGURE 2
on p.280
281FIGURE 3
on p.281
281FIGURE 4
on p.281
282FIGURE 5
on p.282
282FIGURE 6
on p.282
283FIGURE 7
on p.283
283FIGURE 8
on p.283
284FIGURE 9
on p.284

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clutter W. E., Bier D. M., Shah S. D., Cryer P. E. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest. 1980 Jul;66(1):94–101. doi: 10.1172/JCI109840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cryer P. E. Glucose counterregulation in man. Diabetes. 1981 Mar;30(3):261–264. doi: 10.2337/diab.30.3.261. [DOI] [PubMed] [Google Scholar]
  3. Cryer P. E., Haymond M. W., Santiago J. V., Shah S. D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med. 1976 Sep 9;295(11):573–577. doi: 10.1056/NEJM197609092951101. [DOI] [PubMed] [Google Scholar]
  4. Cryer P. E., Rizza R. A., Haymond M. W., Gerich J. E. Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. Metabolism. 1980 Nov;29(11 Suppl 1):1114–1118. doi: 10.1016/0026-0495(80)90019-0. [DOI] [PubMed] [Google Scholar]
  5. Dencker H., Hedner P., Holst J., Tranberg K. G. Pancreatic glucagon response to an ordinary meal. Scand J Gastroenterol. 1975;10(5):471–474. [PubMed] [Google Scholar]
  6. Felig P., Gusberg R., Hendler R., Gump F. E., Kinney J. M., Mulrow P. J. Concentrations of glucagon and the insulin:glucagon ratio in the portal and peripheral circulation. Proc Soc Exp Biol Med. 1974 Oct;147(1):88–90. doi: 10.3181/00379727-147-38286. [DOI] [PubMed] [Google Scholar]
  7. Gerich J., Davis J., Lorenzi M., Rizza R., Bohannon N., Karam J., Lewis S., Kaplan R., Schultz T., Cryer P. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol. 1979 Apr;236(4):E380–E385. doi: 10.1152/ajpendo.1979.236.4.E380. [DOI] [PubMed] [Google Scholar]
  8. Jaspan J. B., Huen A. H., Morley C. G., Moossa A. R., Rubenstein A. H. The role of the liver in glucagon metabolism. J Clin Invest. 1977 Aug;60(2):421–428. doi: 10.1172/JCI108791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jaspan J. B., Polonsky K. S., Lewis M., Pensler J., Pugh W., Moossa A. R., Rubenstein A. H. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon. Am J Physiol. 1981 Mar;240(3):E233–E244. doi: 10.1152/ajpendo.1981.240.3.E233. [DOI] [PubMed] [Google Scholar]
  10. Jaspan J. B., Polonsky K. S., Röjdmark S., Ishida T., Field J. B., Rubenstein A. H. Hepatic extraction of plasma immunoreactive glucagon components. Predilection for 3500-dalton glucagon metabolism by the liver. Diabetes. 1981 Sep;30(9):767–772. doi: 10.2337/diab.30.9.767. [DOI] [PubMed] [Google Scholar]
  11. Kleinbaum J., Shamoon H. Selective counterregulatory hormone responses after oral glucose in man. J Clin Endocrinol Metab. 1982 Oct;55(4):787–790. doi: 10.1210/jcem-55-4-787. [DOI] [PubMed] [Google Scholar]
  12. MacGorman L. R., Rizza R. A., Gerich J. E. Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man. J Clin Endocrinol Metab. 1981 Sep;53(3):556–559. doi: 10.1210/jcem-53-3-556. [DOI] [PubMed] [Google Scholar]
  13. Radziuk J., McDonald T. J., Rubenstein D., Dupre J. Initial splanchnic extraction of ingested glucose in normal man. Metabolism. 1978 Jun;27(6):657–669. doi: 10.1016/0026-0495(78)90003-3. [DOI] [PubMed] [Google Scholar]
  14. Rizza R. A., Cryer P. E., Gerich J. E. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 1979 Jul;64(1):62–71. doi: 10.1172/JCI109464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rizza R., Haymond M., Cryer P., Gerich J. Differential effects of epinephrine on glucose production and disposal in man. Am J Physiol. 1979 Oct;237(4):E356–E362. doi: 10.1152/ajpendo.1979.237.4.E356. [DOI] [PubMed] [Google Scholar]
  16. Rizza R., Verdonk C., Miles J., Service F. J., Gerich J. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man. J Clin Invest. 1979 Jun;63(6):1119–1123. doi: 10.1172/JCI109404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Santiago J. V., Clarke W. L., Shah S. D., Cryer P. E. Epinephrine, norepinephrine, glucagon, and growth hormone release in association with physiological decrements in the plasma glucose concentration in normal and diabetic man. J Clin Endocrinol Metab. 1980 Oct;51(4):877–883. doi: 10.1210/jcem-51-4-877. [DOI] [PubMed] [Google Scholar]
  18. Shamoon H., Hendler R., Sherwin R. S. Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab. 1981 Jun;52(6):1235–1241. doi: 10.1210/jcem-52-6-1235. [DOI] [PubMed] [Google Scholar]
  19. Stacpoole P. W., Jaspan J., Kasselberg A. G., Halter S. A., Polonsky K., Gluck F. W., Liljenquist J. E., Rabin D. A familial glucagonoma syndrome: genetic, clinical and biochemical features. Am J Med. 1981 May;70(5):1017–1026. doi: 10.1016/0002-9343(81)90858-5. [DOI] [PubMed] [Google Scholar]
  20. Tse T. F., Clutter W. E., Shah S. D., Miller J. P., Cryer P. E. Neuroendocrine responses to glucose ingestion in man. Specificity, temporal relationships, and quantitative aspects. J Clin Invest. 1983 Jul;72(1):270–277. doi: 10.1172/JCI110966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Valverde I., Dobbs R., Unger R. H. Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs. Metabolism. 1975 Sep;24(9):1021–1028. doi: 10.1016/0026-0495(75)90095-5. [DOI] [PubMed] [Google Scholar]
  22. Walter R. M., Jr, Gold E. M., Michas C. A., Ensinck J. W. Portal and peripheral vein concentrations of insulin and glucagon after arginine infusion in morbidly obese subjects. Metabolism. 1980 Oct;29(11):1037–1040. doi: 10.1016/0026-0495(80)90213-9. [DOI] [PubMed] [Google Scholar]
  23. von Schenck H., Grubb A. O. Interference of immunoglobulins in two glucagon radioimmunoassays. Clin Chem. 1982 May;28(5):1103–1107. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES